IN THE UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK

REGENERON PHARMACEUTICALS, INC.

Plaintiff,


v.

NOVARTIS PHARMA AG, NOVARTIS TECHNOLOGY LLC, NOVARTIS PHARMACEUTICALS CORPORATION, VETTER PHARMA INTERNATIONAL GMBH

Defendants.

CASE NO.: 1:20-cv-05502-AJN

Hon. Alison J. Nathan



STIPULATION AND [PROPOSED] ORDER MODIFYING CASE SCHEDULE

WHEREAS, Plaintiff Regeneron Pharmaceuticals, Inc. ("Plaintiff") and Defendants Novartis Pharma AG, Novartis Technology LLC, Novartis Pharmaceuticals Corporation and Vetter Pharma International GmbH (collectively, "Defendants") (Plaintiff and Defendants, collectively, "Parties") have been engaged in document discovery in the above-captioned action,

WHEREAS, the Parties agree that they require additional time for substantial completion of document production,

WHEREAS, the Parties have met and conferred and agreed to seek a one-month extension of the current deadline for substantial completion of document productions and all remaining deadlines in the current case schedule (ECF No. 81-2),

IT IS NOW, THEREFORE, HEREBY STIPULATED AND AGREED, by and between the Parties, through their undersigned attorneys and subject to the Court's approval, that:

 The First Amended Case Schedule (ECF No. 81-2) is hereby modified according to the following Second Amended Case Schedule.



SECOND AMENDED CASE SCHEDULE

EVENT	CURRENT DATE	AMENDED DATE
Deadline to Serve Interrogatories	July 1, 2021	August 2, 2021
Deadline for Substantial Completion of Document Productions	July 1, 2021	August 2, 2021
Deadline to Serve Requests for Admission	October 1, 2021	November 1, 2021
Close of Fact Discovery	November 1, 2021	December 2, 2021
Opening Expert Reports Due	December 13, 2021	January 13, 2022
Production of Documents and Data Considered in Experts' Reports	December 20, 2021	January 20, 2022
Rebuttal Expert reports due	February 7, 2022	March 10, 2022
Production of Documents and Data Considered in Experts' Reports	February 14, 2022	March 17, 2022
Reply Expert reports due	March 14, 2022	April 14, 2022
Production of Documents and Data Considered in Experts' Reports	March 21, 2022	April 21, 2022
Close of Expert Discovery	April 14, 2022	May 16, 2022
Summary Judgment/Daubert Motions Due	May 26, 2022	June 27, 2022
Summary Judgment/Daubert Oppositions Due	July 7, 2022	August 8, 2022
Summary Judgment/Daubert Replies Due	August 8, 2022	September 8, 2022

STIPULATED TO AND APPROVED BY:

Dated: June 21, 2021

/s/ Eric S. Hochstadt

Elizabeth Stotland Weiswasser Eric S. Hochstadt Anish R. Desai (pro hac vice)

WEIL, GOTSHAL & MANGES LLP

767 Fifth Avenue

New York, New York 10153-0119

Telephone: (212) 310-8000

Fax: (212) 310-8007

Steven Newborn (pro hac vice)
Michael R. Moiseyev (pro hac vice)
WEIL, GOTSHAL & MANGES LLP

2001 M Street, NW Washington, D.C. 20036

Telephone: (202) 682-7000

Fax: (202) 857-0940

Counsel for Plaintiff Regeneron Pharmaceuticals, Inc.

/s/ Ian Simmons

Ian Simmons

Benjamin G. Bradshaw

O'MELVENY & MYERS LLP

1625 Eye Street, NW Washington, DC 20006 Telephone: (202) 383-5300 Facsimile: (202) 383-5414

Lisa B. Pensabene

O'MELVENY & MYERS LLP

7 Times Square New York, NY 10036 Telephone: (212) 326-2000 Facsimile: (212) 326-2061

Stephen J. McIntyre

O'MELVENY & MYERS LLP

400 South Hope Street Los Angeles, CA 90071 Telephone: (213) 430-6000 Facsimile: (213) 430-6407

Counsel for Defendants Novartis Pharma AG, Novartis Technology LLC, and Novartis Pharmaceuticals Corp.

/s/ Benjamin T. Horton

Benjamin T. Horton Julianne M. Hartzell

MARSHALL GERSTEIN & BORUN LLP

6300 Willis Tower 233 S. Wacker Dr. Chicago, IL 60606 T: 312.474.6300 F: 312.474.0448

Counsel for Defendant Vetter Pharma International GmbH



Casse11220exv0555022AAJJN DDocumeent1.83.31 Filiedc06622122.1 Filiedc06622122.1 Filiedc06622122.1

ORDER

IT IS SO ORDERED this 22nd day of, June 2021.

The Honorable Alison J. Nathan

Alin Q. Notto